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Abstract
Each year diagnostic laboratories in the Netherlands profile thousands of
individuals for heritable disease using next‐generation sequencing (NGS). This
requires pathogenicity classification of millions of DNA variants on the standard
5‐tier scale. To reduce time spent on data interpretation and increase data
quality and reliability, the nine Dutch labs decided to publicly share their
classifications. Variant classifications of nearly 100,000 unique variants were
catalogued and compared in a centralized MOLGENIS database. Variants
classified by more than one center were labeled as “consensus” when
classifications agreed, and shared internationally with LOVD and ClinVar. When
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classifications opposed (LB/B vs. LP/P), they were labeled “conflicting”, while
other nonconsensus observations were labeled “no consensus”. We assessed our
classifications using the InterVar software to compare to ACMG 2015 guidelines,
showing 99.7% overall consistency with only 0.3% discrepancies. Differences in
classifications between Dutch labs or between Dutch labs and ACMG were
mainly present in genes with low penetrance or for late onset disorders and
highlight limitations of the current 5‐tier classification system. The data sharing
boosted the quality of DNA diagnostics in Dutch labs, an initiative we hope will
be followed internationally. Recently, a positive match with a case from outside
our consortium resulted in a more definite disease diagnosis.
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1 | INTRODUCTION
The introduction of next‐generation sequencing (NGS) technol-
ogy in a clinical setting is a challenge for genome diagnostic
laboratories. Two steps of the process are critical. First, the
implementation and validation of the technology itself. Second,
the interpretation of the increasing number of DNA variants
detected, especially when going from small gene panel to whole
exome/genome sequencing (WES/WGS). The latter creates a
significantly larger workload for Clinical Laboratory Geneticists,
spent mainly on variant interpretation.
The nine genome diagnostic labs in the Netherlands, organised
in the VKGL (Vereniging Klinisch Genetische Laboratoriumdiagnos-
tiek, www.vkgl.nl) test thousands of individuals every year using a
standardized interpretation procedure, resulting in classifications
on a 1–5 scale. So far, the classification data were stored locally in
databases, each containing unique observations. These data facil-
itate interpretation of other patient’s variants by providing
classifications of variants that were previously assessed in this
particular genome diagnostic lab. For other variants, after filtering
for potential pathogenicity, various databases are consulted such as
Human Gene Mutation Database (HGMD; Stenson et al., 2017),
Leiden Open Variation Database (LOVD; Fokkema et al., 2011) and
ClinVar (Landrum et al., 2016) as well as resources such as
PubMed (Fiorini, Lipman, & Lu, 2017) and OMIM (Amberger,
Bocchini, Schiettecatte, Scott, & Hamosh, 2015). In the absence of
a positive hit or any clear in silico prediction of the variant effect,
clinicians have to resort to contacting their peers in other
diagnostic labs to determine whether they have seen these variants
before. This approach does not scale with the current and ever‐
increasing data volumes that have come with the introduction of
NGS in the clinic. To overcome this limitation, the Dutch labs
decided to share all interpreted variants and develop a platform to
facilitate this process.
Implementation of a platform for sharing interpreted variants is far
from trivial. Apart from foreseen technical challenges, such as the
integration of novel software with existing diagnostic processes, there
are also logistic demands; clinicians and laboratory personnel should not
be burdened with the additional task of sharing variants and variant
classification results. It also requires a significant amount of effort to
agree on what data to share, under which conditions these may be
shared, and for which purposes the data may be used, all in agreement
with applicable laws and regulations on both national and international
level. Finally, the resulting platform should not be limited by a specific
technology that might exclude or otherwise obstruct participating
laboratories and hinder further international collaboration.
The Dutch genome diagnostics labs from the Amsterdam UMC
(Amsterdam University Medical Center, locations AMC [Academisch
Medisch Centrum] and VUmc [Vrije Universiteit Medisch Centrum]),
ErasmusMC (Erasmus Medical Center), UMCG (University Medical
Center Groningen), LUMC (Leiden University Medical Center), Maas-
tricht UMC+, NKI (Netherlands Cancer Institute), RadboudUMC and
UMCU (University Medical Center Utrecht) have combined their efforts
to create a national platform for sharing variants and their interpreta-
tions. Here, we present the platform we have developed using open
source MOLGENIS software (MOLecular GENetics Information System;
van der Velde et al., 2019), the problems we encountered and the
solutions chosen. This platformminimizes the impact on the workload of
the participating diagnostic labs by automating many labor‐intensive
and repetitive tasks such as collecting variants and assigning consensus
status, significantly improving data visibility, data quality and reliability
of variant classifications on a national level. On an international level,
the nonconflicting classifications have also been shared with the variant
database LOVD (Leiden Open Variation Database), and consensus
classifications have been shared with ClinVar, maximizing the utilisation
of the collected data. Sharing on an international level resulted in a first
example where the VKGL data sharing helped to resolve an initially
unresolved case.
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2 | MATERIALS AND METHODS
2.1 | Uploading variants from participating
diagnostic centers
The variants provided by the participating labs were classified
according to VKGL guidelines (Wallis et al., 2013). Software used
to locally collect variant classifications include Agilent Alissa
Interpret (Agilent Technologies, formerly Cartagenia) and LOVD+
whole‐exome analysis software. Tools and software supporting
variant classification include Alamut (Interactive Biosoftware),
in‐house databases, literature searches, functional effect predic-
tion, population databases (1,000 G (1000 Genomes Project
Consortium et al., 2015), ExAC (Lek et al., 2016), ESP6500
(Tennessen et al., 2012), GnomAD (Karczewski et al., 2019),
GoNL (Francioli et al., 2014)), and Human Genome Mutation
Database professional (HGMD; Stenson et al., 2017). We based
the fields required to describe each variant on the VCF file
format (Danecek et al., 2011). This format describes each
sequence variant by their chromosome, genomic position, a
reference string of the nucleotide(s) present in the reference
sequence at the given position (REF), and the observed alternate
nucleotide sequence (ALT). The given position refers to the first
nucleotide of the reference string. In addition to these fields,
each center provided the annotated HGNC gene symbol, the
annotated transcript, the variant description based on the HGVS
recommendations (den Dunnen et al., 2016) and the variant’s
classification using the common 5‐tier system (Plon et al., 2008;
Richards et al., 2015; Wallis et al., 2013). All data were collected
in an TSV or CSV file and uploaded to the central server.
The centers that could not provide the VCF fields because their
analysis platform used the HGVS format, shared the HGVS‐based
variant descriptions. These were then converted into VCF fields
using the Mutalyzer service (https://mutalyzer.nl/).
2.2 | Unique variant descriptions (VCF and HGVS)
While VCF files are adequate for exchanging variant data, various
sequencing pipelines and analysis platforms may store and
exchange the same variant in different formats. For example, a
duplication of the G in AGCT could be described as position 1 A
to AG, as position 2 G to GG, or as position 3 C to GC. HGVS
nomenclature uses much stricter rules for variant descriptions, in
this case allowing only the description g.2dup. To exclude the
possibility that identical variants were described in more than
one way, we decided to perform an additional quality check. All
variants were sent to Mutalyzer’s JSON API to generate
unambiguous HGVS descriptions. As Mutalyzer expects HGVS
descriptions as input, variants described using the VCF format
were first converted into an HGVS description, after which they
were submitted to Mutalyzer’s API for normalization to non-
ambiguous HGVS variant descriptions.
2.3 | Grouping the submissions and verifying
consensus classification
After uploading the variants and checking the classifications, the data
was processed by a program that compares the classifications and
creates the consensus classification (https://github.com/molgenis/
molgenis‐projects/tree/master/VKGL/scripts/consensus). In this step,
because subsequent clinical action does not differ between likely
benign and benign or likely pathogenic and pathogenic, a 3‐tier
classification system was applied rather than a 5‐tier system.
Classifications in this 3‐tier system were: likely benign/benign, variant
of uncertain significance (VUS) and likely pathogenic/pathogenic. When
different centers provided opposite classifications (i.e., [likely] benign
and [likely] pathogenic), the variant was marked as “opposite classifica-
tion.” Variants classified as VUS by one center and either (likely) benign
or (likely) pathogenic by another were marked as “no consensus.”
Variants seen by more than one center and providing the same
classification were marked as “consensus,” a status not given to variants
submitted by only one participant. Variants only seen by one lab are set
to ‘Classified by one lab.’
2.4 | Setting up the national diagnostics variant
database
The variant classifications from all VKGL centers were collected and
shared via the national diagnostics variant database (http://molgenis.org/
vkgl). The database was setup using the MOLGENIS software platform
for scientific data (http://molgenis.org). After importing newly contrib-
uted data, the platform automatically generates statistics on the number
of single‐lab submissions, consensus variants, and variants with no or
conflicting classifications. Highlighting the conflicting classifications
allows curators and labs to quickly pinpoint variants that require
reinterpretation, where possible resolving the conflict status to a
consensus status for the next release of the database. New releases
are produced every 3 months. The database is updated by creating new
tables for each lab with their latest data. From those tables a new
consensus table is created. All tables are versioned with the date, and all
previous versions of the tables are kept for future reference.
To aid variant classification, the Dutch diagnostic centers
using Alissa Interpret received an extract of the central database
to be imported in their analysis software. The diagnostic center in
Leiden, using the LOVD + whole exome analysis software, re-
ceived access to the consensus data and single lab submissions
through the link with the LOVD variant sharing platform.
Maastricht UMC+ and RadboudUMC received an export of the
data and imported it in their shared classification database, which
is connected to their interpretation software.
2.5 | Sharing the variants with ClinVar and LOVD
Variants for which consensus was reached were shared with ClinVar
(Landrum et al., 2016) and LOVD (Fokkema et al., 2011); additionally,
single lab submissions were shared anonymously with LOVD. For
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ClinVar, each center created a submission account. The VKGL project
data manager was added to the organization of all centers to be able to
submit the variants for them. Submission sheets for ClinVar (https://
www.ncbi.nlm.nih.gov/clinvar/docs/submit/) were created from the
MOLGENIS database using an export script (https://github.com/
molgenis/molgenis‐projects/tree/master/VKGL/scripts/clinvar_export).
Only variants with one OMIM code attached to the related gene and for
which consensus was reached were submitted to ClinVar (https://www.
ncbi.nlm.nih.gov/clinvar/?term=VKGL+Data‐share +Consensus). Var-
iants with multiple OMIM codes were not submitted because of their
ambiguous association to disease. Variants from single lab submissions
were not submitted to ClinVar to prevent identifiability; ClinVar does
now allow anonymous submissions. To easily find the data in ClinVar
and to emphasize that this classification was based on multiple
evaluations, all submissions were labelled as “VKGL Data‐share
Consensus.” The original 5‐tier classifications of the submitting centers
were used for the ClinVar submission, rather than the 3‐tier
classifications generated in the VKGL database consensus table. We
intend to update the data in ClinVar when new data becomes available.
For sharing with LOVD, a submitter account was created for each
participating lab on the “Global Variome shared LOVD” installation
(http://LOVD.nl/shared). All nonconflicting variants, including single
lab classifications, were shared and imported into LOVD using an
import script (https://github.com/LOVDnl/VKGL_import), which also
handles updates of the data in LOVD after every new data release.
Consensus data had the data of each lab linked to their own account.
To indicate their status, variants were labeled as “classification
records”, not linked to an individual or a specific phenotype.
2.6 | Classification assessment using ACMG2015
guidelines
We assessed the classifications made by the VKGL labs by comparing
them with InterVar (Li & Wang, 2017) as a second‐opinion tool
(version 2.0.2 20180118 downloaded from https://github.com/
WGLab/InterVar). The InterVar tool is an automated implementation
of the ACMG2015 guidelines. The InterVar classifications were
compared to the VKGL classifications in two subsets: (a) only
consensus variants, and (b) only variants submitted by one center. A
discrepancy in classification is defined as when one variant is
classified as likely benign/benign in one data set, and as likely
pathogenic/pathogenic in the other. The output classification was
compared with the VKGL classification with a program that checks
discrepancies (available at https://github.com/joerivandervelde/vkgl).
3 | RESULTS AND DISCUSSION
3.1 | Setting up the national diagnostics variant
database
The Dutch genome diagnostic laboratories decided to share their
variant classifications to facilitate the clinical interpretation of
variants encountered in daily genetic analyses. Each center’s
classified variants were uploaded to the national VKGL MOLGENIS
database (http://www.molgenis.org/vkgl). Users can browse the
database or query it using different options including gene name,
variant description and genomic locations. For each variant the
reporting labs are shown, and the classifications provided. This
database is the bridgehead for dissemination of the variant
classifications from the Dutch diagnostic labs, both nationally and
internationally.
After uploading all variants, the database contained 97,801
unique variants (release 31‐05‐2018). Most of these, 82,898, were
reported by one lab only. Fourteen thousand nine hundred and three
variants were reported by more than one lab (from two to seven
independent observations from eight potential sources). See Figure 1
for a graphical overview of the classifications in the VKGL database.
3.2 | Unique variant descriptions (VCF and HGVS)
The variety in analysis tools in use (and those that may come in the
future) requires a flexible approach to data sharing, as there is not
one format supported by all tools, and not all formats require the
same variant description fields. Here, we used the fields defined
within the VCF file format to describe each variant, as VCF is the
most commonly used file format for large‐scale genomic variant
sharing. The variants were also converted into HGVS notation to
allow consistency checking because VCF notation may be ambiguous.
A quality check was performed to verify the uniqueness of
variant descriptions (e.g., g.2dup and g.2_3insG, see Section 2). We
encountered 2,498 cases of alternative variant descriptions, leading
to a drop of unique variants by 1,498 (1.5% of total) and an increase
of 391 consensus variants (3.0% of consensus variants). As expected,
most problematic were insertions that should be described as
duplications and identical deletions or insertions where the nucleo-
tide positions specified differed. One such example is
NC_000019.9:g.13318710_13318712del, which was described by
five centers in eight different ways. Other examples include
substitutions described in the VCF file format as deletion‐insertion
F IGURE 1 Overview of VKGL variant classifications. Data is split
depending on whether a variant was classified and submitted to the
database by two or more labs, or by only one lab. VKGL, Vereniging
Klinisch Genetische Laboratoriumdiagnostiek
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events. These figures show that when comparing multiple data sets,
disambiguation is an important step that should not be overlooked.
As such, a future release of our pipeline will automatically
disambiguate all submitted variants.
It should be noted that when variant descriptions are not correct,
queries to find them in public repositories will also fail, hampering
correct and accurate variant classification. Although variant data-
bases ClinVar and LOVD are aware of this problem, storing all
alternative descriptions of a variant is not feasible as there are
unlimited possibilities. Although variant databases could collect at
least confirmed alternative notations for the same variant, as LOVD
does in case there is a known alternative notation, this can never be
exhaustive.
3.3 | Consistency of classification in VKGL
consortium
Comparing variant classifications (see Section 2) we observed that
12,965/14,903 (87%) variants with more than one submission had a
consensus classification, 1,866 (12.5%) a nonconsensus classification
and 72 (0.5%) a conflicting classification (see Figure 1).
After each release, all laboratories were notified of the
classifications from their lab that conflicted with other classifications
in the central database. Upon receiving this list, conflicts could be
resolved by direct contact between the laboratories. Updated
classifications were stored in each lab’s own system, and the conflict
was resolved in the next release. Since the implementation of the
database, a total of 173 conflicting classifications have been resolved.
In most cases, the date of classification turned out to be the culprit.
Most laboratories have been performing diagnostic genetic tests for
over 30 years. Classifications during the early days made use of far
less information than we do now, for example by using a large body
of reference literature and other resources such as ExAC/gnomAD,
enabling a more specific classification.
Another category consists of variants that were classified as
pathogenic by one lab but as VUS or even likely benign by another
lab based on the fact that the variant has a low penetrance.
In this case, reporting differed simply because clear guidelines
for such cases are currently lacking. For example, the
NM_025216.2:c.337C>T NP_079492.2:p.(Arg113Cys) variant in
WNT10A is considered a pathogenic variant for the autosomal
dominant and recessive inherited Tooth agenesis (MIM#150400).
This is a low penetrant disorder; however, and the variant is present
in 238 alleles (236 heterozygotes and one homozygote, out of
282,532 alleles observed) in the gnomAD database. Similar problems
emerged when clearly deleterious variants are encountered in
pharmacogenetic genes—should these be classified as benign or
pathogenic, or should another class be added such as “risk factor,
drug metabolism”?
We investigated the possibility of determining consensus
classification by majority vote, where consensus could be reached
when at least 75% (a ratio of 3:1) of the centers agreed. For this, at
least four classifications were needed but very few variants in our
data had been reported by four centers or more. We found that only
an additional 0.15% of all variants could have been considered in
consensus when applying majority vote, so this method was
ultimately not used.
3.4 | Assessing the quality of classifications
provided
Since variant databases like ClinVar or LOVD are often consulted in
Dutch genome diagnostic labs for existing classifications, they are not
a good source for assessing the quality of the VKGL laboratory
variant classifications. Moreover, many Dutch variants may not be
present in these resources, or the variants are submitted by Dutch
labs themselves. As such, to assess the classifications made by the
VKGL laboratories, we compared them with those obtained through
InterVar. We processed our data through InterVar, made sure that
the reported variant was in agreement with the GRCh37/hg19
reference genome, matched VKGL gene names with InterVar gene
names, and removed variants with nonconsensus VKGL classifica-
tions, resulting in 82,111 variants. Of these, 11,910 variants (a subset
of the 12,965 variants mentioned above) were seen by multiple labs
and 70,201 by single labs (see Figure 2).
The results show 99.7% overall consistency with InterVar, with
only a few discrepancies. Significant discrepancies (LB/B‐LP/P
swaps), were observed in only 0.15% of the consensus variants,
0.33% in case of single‐lab submissions and 0.3% across all variants
combined. See Table 1. However, it is worth noting that differences
between VUS and LB/B/LP/P were not counted as discrepancies,
accounting for 30% of total variants included in the discrepancy
analysis. As InterVar was used in a fully automated method and did
not have access to any of the specifics such as the de novo status or
segregation of a variant, it resorted to classifying a variant as VUS
more often than the specialists manually curating the variant in the
scope of a single patient.
The top VKGL‐InterVar discrepant genes are shown in Table 2.
This table also indicates a number of opposing classifications for
these genes within VKGL that were not used in the discrepancy
analysis with InterVar. We investigated the overlap between genes
that had none or at least one VKGL opposing classifications, with
genes that had none or at least one VKGL‐InterVar discrepancy. We
found a strong association (odds ratio of 21.94 with 95% confidence
interval [CI] 11.34‐41.30 and p value 3.019e−16) for genes that are
VKGL‐InterVar conflicting as these also have opposite classifications
in the VKGL consensus list effort and vice versa in Table 3, showing
that these 18 genes (SCN5A, SLCO1B1, VWF, ERCC2, SPTA1,
ABCG8, WNT10A, MYBPC3, PKHD1, APOE, TTN, ATP7B, MITF,
LPL, FIG. 4, MYO1A, LMF1, and SCN9A) are consistently problematic
for variant interpretation.
If the VKGL‐InterVar discrepancies were randomly distributed
among all variant classifications, one would expect a linear relation
between the number of variants and the number of discrepancies per
gene. A regression analysis indeed shows a trend; however, the
explained variation is less than 9% (see Figure 3). This means the
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discrepant classifications are not distributed fully randomly and may
in part be explained by other causes. Closer examination attributes
the discrepancies mainly to variants that had a clear functional
consequence but were associated with low risk of disease, like
hypercholesterolemia and familial Mediterranean fever or low
penetrant variants in late onset disorders like cardiomyopathy. For
instance, the pathogenic NM_000256.3:c.3628‐41_3628‐17del var-
iant in MYBPC3 that leads to exon 33 skipping, has a MAF in the
Indian population of 4% (Dhandapany et al., 2009), underlining the
limitations of the 5‐tier classification system for low penetrant and
late onset disorders. Nonetheless, the majority (99.7%) of inter-
pretations did not conflict, thus we consider in silico interpretation
tools such as InterVar a worthwhile second opinion for variant
analysis pipelines. The 0.3% conflicting interpretations may be
partially solved if more information such as familial segregation,
family history, and de novo status would be included in a manually
adjusted two‐Step InterVar analysis.
3.5 | Five‐tier classification limits
The classification conflicts discussed, both between Dutch labs and
Dutch labs compared with ACMG, highlight the limits of the current
5‐tier classification system. Multiple studies have already published
gene‐ or disease‐specific updates to the ACMG guidelines (Gelb et al.,
2018; Kelly et al., 2018; Romanet et al., 2019). While these studies
adapt the guidelines for low‐frequency disorders, also for more
frequent or less‐penetrant disorders the classification system might
be less unequivocal. ClinVar and LOVD already have additional terms
such as “association,” “risk factor,” “protective,” “affects function,”
“drug response,” “linked to nondisease phenotype.” One of the
solutions could be to divide the classifications into two separate
groups. A functional/molecular classification based on the
F IGURE 2 Flowchart describing the steps and results of the
VKGL‐InterVar discrepancy analysis. VKGL, Vereniging Klinisch
Genetische Laboratoriumdiagnostiek
TABLE 1 Consensus and single lab classification discrepancies with InterVar
VKGL variant
interpretation
InterVar
classification VKGL B/LB VKGL P/LP VKGL VUS
Consensus only InterVar B/LB 8,892 18 121
Consensus only InterVar P/LP 3 679 34
Consensus only InterVar VUS 1,048 362 753
Single‐lab only InterVar B/LB 26,195 164 1,814
Single‐lab only InterVar P/LP 69 5,629 859
Single‐lab only InterVar VUS 15,718 4,695 15,058
Consensus + single‐lab InterVar LB/B 35,087 182 1,935
Consensus + single‐lab InterVar LP/P 72 6,308 893
Consensus + single‐lab InterVar VUS 16,766 5,057 15,811
Note: There are 11,910 variants submitted by multiple VKGL centers that reached full consensus classification (Consensus only), of which we found 0.15%
LB/B‐LP/P discrepancies when comparing their classification with InterVar. Additionally, there are 70,201 variants classified by a single VKGL center
(Single‐lab only), of which we found 0.33% LB/B‐LP/P discrepancies when comparing their classification with InterVar. In total, there are 82,111 variants
classified by either single‐labs or in consensus by multiple VKGL centers (Consensus + single‐lab), of which we found 0.3% LB/B‐LP/P discrepancies when
comparing their classification with InterVar.
Abbreviation: VKGL, Vereniging Klinisch Genetische Laboratoriumdiagnostiek.
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consequence of the variant for the function of the gene, RNA or
protein, and a clinical classification based on the consequences of the
variant for the health of the individual. Revising or creating
international guidelines on this topic would be welcome to prevent
“conflicting” classifications and misdiagnoses.
3.6 | Sharing with international databases
Key to increasing the value of shared data, is to increase the audience
with which it is shared. In this light, the VKGL labs decided to share
variant classifications internationally, with ClinVar and LOVD. These
databases are well‐known international repositories used indepen-
dently by clinics and researchers. Both have implemented a range of
options to access the data, including API access and the GA4GH’s
beacon project (Global Alliance for Genomics & Health, 2016), and
can be accessed using various genome browsers. Sharing variants via
these platforms instantly connects our data with their users while
efficiently using existing complex APIs and networks. Moreover,
these international databases are used as sources for annotation in
sequencing analysis pipelines and annotation services like Ensembl’s
Variant Effect Predictor (McLaren et al., 2016); by sharing variant
classifications, the pool of classified variants that can be used as the
training set for new or existing algorithms is also increased.
Upon depositing our data in LOVD, we quickly experienced a
positive outcome of our sharing effort. A variant in the RPGRIP1
gene, linked to cone‐rod dystrophy and Leber congenital amaurosis,
classified as VUS, was picked up by a clinical geneticist from
Baltimore (Maryland), United States. Whole‐exome sequencing of a
10‐year old boy with severe retinopathy had revealed a homozygous
NM_020366.3:c.1948C>T change in RPGRIP1. This single observation
could not be used to classify this variant as pathogenic. However,
since the variant was identified twice in the VKGL data set, and
since the clinical features of all patients were similar, the classifica-
tion could be changed from VUS to likely pathogenic. This first
success of our data sharing efforts emphasize its importance, even on
a global scale.
3.7 | Evaluation of data sharing initiative by
questionnaire
To obtain a human measure of success for our data sharing initiative,
we sent out a questionnaire to VKGL members who use the shared
data as part of their daily work. The questions were filled out
anonymously except for affiliation. We received responses from 32
members representing all nine participating laboratories (see
Supporting Information 1). We found that 87.5% of respondents
use the VKGL shared variant classifications directly through the in‐
house software used in their laboratory, such as Alissa, but that the
central MOLGENIS database was also used by 40.7% of members.
Respondents have a predominantly positive opinion about data
sharing: 78.1% indicated it has helped their interpretation, 75.0%
experienced the resolving of discrepancies and thereby improved
TABLE 2 Top VKGL‐InterVar conflicting genes
Gene
VKGL total number of
classifications
VKGL‐
Intervar
conflicts
Consensus VKGL
P→ InterVar B
1 VKGL lab
B→ InterVar P
1 VKGL lab
P→ InterVar B
VKGL opposing
classifications
APOB 407 9 0 0 9 0
PCSK9 163 9 0 0 9 0
LDLR 300 9 0 0 9 0
NF1 908 5 0 2 3 0
PAH 115 5 0 0 5 0
SCN5A 352 5 0 1 4 1
MEFV 290 4 3 0 1 0
SLCO1B1 76 4 0 1 3 1
STS 10 3 0 3 0 0
APOA5 33 3 0 0 3 0
Note: The genes with the most VKGL‐InterVar classification conflicts are APOB, PCSK9, and LDLR, each with nine conflicts. Across 82,111 investigated
variants we found 254 conflicts (shown here: 56), of which 21 originated from consensus variants (shown here: 3).
Abbreviation: VKGL, Vereniging Klinisch Genetische Laboratoriumdiagnostiek.
TABLE 3 Contingency table
One or more VKGL‐InterVar discrepant variants No VKGL‐InterVar discrepant variants
One or more VKGL opposing classifications 18 32
No VKGL opposing classifications 155 6,059
Note: Fisher’s exact test shows odds ratio of 21.94 (95% confidence interval: 11.34‐41.30, p value: 3.019e−16). This shows strong enrichment for genes
that are VKGL‐InterVar conflicting to also contain opposite classifications in VKGL consensus data.
Abbreviation: VKGL, Vereniging Klinisch Genetische Laboratoriumdiagnostiek.
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variant classification, and 93.7% thinks that the initiative has some
(score 2 out of 5) to exceptional (score 5 out of 5) added value for
molecular diagnostics in the Netherlands. In addition, 81.2% of
respondents indicated that a small (score 2 out of 5) to a huge (score
5 out of 5) amount of time was saved in classifying variants.
4 | CONCLUSIONS
With the establishment of the sharing system presented, we have
streamlined our diagnostic process, increased standardization,
reduced time spent on data interpretation/variant classification and
achieved an overall improved quality and reliability. We learnt how
to ensure correct variant descriptions, reducing the chance of
identical observations being missed, and experienced how the
limitations of the current 5‐tier system led to seemingly conflicting
classifications. Finally, our aim has been to improve overall diagnosis
for patients and their families by internationally sharing our
unpublished observations. Who will join our initiative?
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